- Home
- SCPH vs FDMT Comparison
SCPH vs FDMT Comparison
Compare SCPH & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- FDMT
- Stock Information
- Founded
- SCPH 2013
- FDMT 2013
- Country
- SCPH United States
- FDMT United States
- Employees
- SCPH N/A
- FDMT N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- SCPH Health Care
- FDMT Health Care
- Exchange
- SCPH Nasdaq
- FDMT Nasdaq
- Market Cap
- SCPH 173.6M
- FDMT 192.2M
- IPO Year
- SCPH 2017
- FDMT 2020
- Fundamental
- Price
- SCPH $4.85
- FDMT $7.09
- Analyst Decision
- SCPH Strong Buy
- FDMT Buy
- Analyst Count
- SCPH 3
- FDMT 9
- Target Price
- SCPH $14.00
- FDMT $30.63
- AVG Volume (30 Days)
- SCPH 322.0K
- FDMT 2.6M
- Earning Date
- SCPH 08-07-2025
- FDMT 08-11-2025
- Dividend Yield
- SCPH N/A
- FDMT N/A
- EPS Growth
- SCPH N/A
- FDMT N/A
- EPS
- SCPH N/A
- FDMT N/A
- Revenue
- SCPH $49,969,000.00
- FDMT $33,000.00
- Revenue This Year
- SCPH $108.95
- FDMT $9,921.62
- Revenue Next Year
- SCPH $73.83
- FDMT N/A
- P/E Ratio
- SCPH N/A
- FDMT N/A
- Revenue Growth
- SCPH 107.79
- FDMT N/A
- 52 Week Low
- SCPH $1.94
- FDMT $2.24
- 52 Week High
- SCPH $6.28
- FDMT $17.41
- Technical
- Relative Strength Index (RSI)
- SCPH 51.56
- FDMT 65.24
- Support Level
- SCPH $4.33
- FDMT $6.35
- Resistance Level
- SCPH $4.82
- FDMT $7.59
- Average True Range (ATR)
- SCPH 0.35
- FDMT 0.59
- MACD
- SCPH -0.07
- FDMT 0.05
- Stochastic Oscillator
- SCPH 49.55
- FDMT 78.81
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.